1. Introduction
===============

Human papillomavirus (HPV), the most extensively studied virus of the past decade, is composed of a particularly heterogeneous family of DNA viruses, which has the ability to infect keratinocytes of the human skin and mucosa ([@b1-ol-08-02-0502]). HPV, which appears to invade the basal layer of epithelial cells, is a common pathogen associated with a wide range of cutaneous and mucosal infections ([@b2-ol-08-02-0502]). HPV can be transmitted through physical contact via autoinoculation or fomites, sexual contact, as well as vertically from the HPV-positive mother to her newborn and can cause subclinical or clinical infections ([@b1-ol-08-02-0502],[@b2-ol-08-02-0502]). HPV-associated clinical infections include skin warts, genital warts, recurrent respiratory papillomatosis (RRP), low-grade and high-grade squamous intraepithelial lesions (SILs) and cervical cancer, which globally represents the second most frequent cancer in females ([@b3-ol-08-02-0502]).

In infancy and childhood, HPV infection involving skin warts, genital warts and juvenile RRP among both male and female neonates and children, as well as cervical SILs among adolescent girls ([Fig. 1](#f1-ol-08-02-0502){ref-type="fig"}), has been excessively investigated \[see reviews by Mammas *et al* ([@b2-ol-08-02-0502]) and Syrjänen ([@b4-ol-08-02-0502])\]. This scientific effort began in 1978, almost 35 years ago, when the first report involving children in HPV research was published by Pfister and zur Hausen ([@b5-ol-08-02-0502]). To date, several researchers, worldwide, have studied HPV from the paediatric point of view, expanding the usage of molecular techniques, such as the polymerase chain reaction (PCR) in samples obtained from children. During the past years, a great expansion has taken place in the field due to the introduction of the vaccination programmes against HPV into clinical practice. In this review, we briefly summarize some of the historical aspects of peadiatric HPV research until the time point of this great expansion.

2. Historical background
========================

HPV-associated lesions, including skin and genital warts, have been reported since ancient times ([@b6-ol-08-02-0502]). In the 4th century B.C. Hippokrates the Asclepiad, first described skin warts, genital warts and cervical neoplasia ([@b6-ol-08-02-0502]--[@b8-ol-08-02-0502]). Although Hippokrates was certainly not the first to discover cervical neoplasia, he referred to a cervical lesion, which in Greek is termed 'ἔλκoς' ([@b6-ol-08-02-0502]), meaning 'ulcer' that can potentially progress to cervical cancer, indicating that HPV-associated SILs can progress to invasive cervical cancer. This knowledge referring to the physical history of HPV infection in the cervix is apparent in the impressive description by Hippokrates: 'ɛἰ δὲ μὴ ἐμɛλɛδάνθη, μηδὲ oἱἡ κάθαϱσις ἐϱϱάγη αὐτόματη, τὸἓλκoς μέζoν ἐπoίησεν καὶ μὴ ἀνει】σα ἑκινδὸνɛυσɛν ɛἰς τὸ καϱϰινωθη̑ναι τὰ ἓλκɛα' ([@b7-ol-08-02-0502]), meaning that 'if it (the infection) is not taken care of, catharsis will not take place automatically, and thus the ulcer will increase in size and if it does not regress, there is a risk of the ulcers becoming cancerous'.

Despite the fact that skin and genital warts have been considered infectious since this early period, the development of cervical cancer due to infection was only suspected in the 19th century A.C. by an Italian scientist from Asiago, Italy, the surgeon Antonio Domenico Rigoni-Stern ([@b9-ol-08-02-0502]). In 1928, a Greek scientist originating from the island of Euboea, Dr George N. Papanicolaou \[a brief referral to his life is presented in the article by Mammas and Spandidos ([@b10-ol-08-02-0502])\] observed precancerous HPV-associated lesions in vaginal smears collected from females, an observation which led to the development of the Pap smear test ([@b11-ol-08-02-0502],[@b12-ol-08-02-0502]). The first description of HPV was provided in 1949 by Strauss *et al* ([@b13-ol-08-02-0502])*,* who used electron microscopy to examine aqueous extracts of wart tissues, while in 1963 the physical properties of HPV DNA were described in the study by Crawford and Crawford ([@b14-ol-08-02-0502]). It was not until the 1970s, that a role of HPV in cervical cancer was postulated for the first time by Professor Harald zur Hausen, the 'Father of HPV Virology' ([@b3-ol-08-02-0502]). It is currently well established that HPV is involved in human carcinogenesis, causing not only the vast majority of cervical, but also a substantial proportion of other non-genital cancers ([@b15-ol-08-02-0502]).

3. HPV in children: a brief overview
====================================

Although the infectious cause of warts in children was known by the end of the 19th century ([@b16-ol-08-02-0502]), initial studies on children using molecular hybridization techniques were performed in the end of the 1970s. In an early study by Pfister and zur Hausen ([@b5-ol-08-02-0502]) in 1978, it was well documented that HPV 1, HPV 2 and HPV 3 predominate in skin warts in children between the ages of 5 and 15 years, while HPV 4 is most often isolated in children of older ages. As is presented in [Table I](#tI-ol-08-02-0502){ref-type="table"}, this article was the first in the literature ([@b5-ol-08-02-0502],[@b17-ol-08-02-0502]--[@b50-ol-08-02-0502]) involving samples obtained from children in HPV research. Evidence of the presence of HPV in juvenile RRP also dates back to the beginning of the 1980s ([@b17-ol-08-02-0502]--[@b19-ol-08-02-0502]). These studies have provided strong evidence of the etiology of tumors caused by HPV that was verified by subsequent studies on RRP.

During the second half of the 1980s, a clear picture of the presence of specific types of HPV in genital warts in children was obtained ([@b21-ol-08-02-0502],[@b22-ol-08-02-0502],[@b24-ol-08-02-0502]). These initial reports enthusiastically supported HPV typing as an important prognostic tool for HPV-infected children, particularly in those infected with HPV 16 and HPV 18, due to the highly oncogenic potential of these two HPV types ([@b24-ol-08-02-0502]). For this reason, at that time, several paediatric departments were requesting HPV typing in cases with genital warts in order to identify children who were at a risk of developing cancer. At the same time, researchers evaluated the impact of the presence of HPV in the diagnosis of sexual abuse. However, early enough, it was made clear that HPV typing using molecular techniques is not sufficient to determine the source of HPV infection and pursue the possibility of sexual abuse ([@b24-ol-08-02-0502],[@b26-ol-08-02-0502],[@b27-ol-08-02-0502]). In the study by Padel *et al* ([@b27-ol-08-02-0502]), it was well established that HPV typing does not provide substantial evidence of the presence or absence of sexual transmission.

The presence of HPV DNA in asymptomatic neonates was initially documented in foreskins by Roman and Fife ([@b20-ol-08-02-0502]). Soon after the report in 1988 by Steinberg ([@b23-ol-08-02-0502]) addressing the transmission of HPV to the fetus, a number of studies investigated the perinatal modes of HPV transmission in childhood ([@b25-ol-08-02-0502],[@b29-ol-08-02-0502]). These studies supported a vertical transmission mechanism of HPV in children based on the presence of HPV DNA in asymptomatic neonates in oral and genital samples at or shortly after birth ([@b25-ol-08-02-0502]). The detection of HPV DNA in the amniotic fluid also suggested an *in utero* mechanism of HPV transmission ([@b25-ol-08-02-0502]). Smith *et al* provided evidence indicating the prevalence of HPV among pregnant women increases with the gestational age from 8.0% in the first trimester to 23.1% in the third trimester ([@b29-ol-08-02-0502]), while, in 1994, Kaye *et al* ([@b32-ol-08-02-0502]) suggested that viral load is a determinant for HPV transmission to the neonate. In the study by Fredericks *et al* ([@b30-ol-08-02-0502]) in 1993, it was well established that the contamination of neonates occurs commonly at birth and persists for at least 6 weeks. In a subsequent report in 1995 by Cason *et al* ([@b33-ol-08-02-0502]), the authors supported a bimodal distribution of IgM seropositivity, which peaked between 2 and 5, and 13 and 16 years of age, suggesting that two distinct modes of transmission may occur. Perinatal HPV in infants has also been shown to be related to the mode of delivery and it was suggested that neonates are at a higher risk of exposure to HPV after vaginal delivery than after caesarean delivery ([@b35-ol-08-02-0502]).

In 1998, a research team from the University of Turku School of Medicine in Finland, initiated the Finnish Family HPV Study, which was the first prospective attempt to assess HPV dynamics at multiple anatomical sites in parents and infants ([@b37-ol-08-02-0502]). The large number of mother-infant pairs analyzed made it possible to explore the consequences of the presence of HPV in the placenta, umbilical cord blood and breast milk. Studies supporting perinatal HPV transmission have been reviewed by two separate research teams, one at the Department of Virology at Kings College in London, UK ([@b51-ol-08-02-0502]) and the other at the University of Turku, Finland ([@b52-ol-08-02-0502]). However, these reports ([@b51-ol-08-02-0502],[@b52-ol-08-02-0502]) have been met with skepticism as regards definitive interpretation. Nevertheless, the potential impact of early acquired HPV neonatal infection on the efficacy of current vaccines for HPV-positive children remains undetermined.

The early findings by Jenison *et al* ([@b28-ol-08-02-0502]) in the 1990s that HPV types exist in the oral cavity of asymptomatic children were re-evaluated a decade later. In 2000, Rice *et al* ([@b36-ol-08-02-0502]) reported the presence of HPV in oral samples obtained from healthy children, while other researchers documented tonsillar tissue as a reservoir of HPV DNA ([@b38-ol-08-02-0502]--[@b40-ol-08-02-0502]). These findings attracted the attention of Reuters Health, raising questions concerning the modes of HPV transmission in childhood ([@b53-ol-08-02-0502]). Moreover, the presence of HPV in the lower tract in children may be involved in the recent increasing scientific interest of the role of HPV in lung carcinogenesis ([@b47-ol-08-02-0502]). Despite the detection of HPV DNA in human breast samples ([@b41-ol-08-02-0502]), it was clarified that this event is rare and there is no contraindication of HPV-positive mothers to breast feed their children ([@b43-ol-08-02-0502],[@b44-ol-08-02-0502],[@b48-ol-08-02-0502],[@b49-ol-08-02-0502]).

In the following years, our research led out to the detection of novel HPV types, including HPV 13, HPV 39, HPV 40 HPV 56, in juvenile RRP ([@b45-ol-08-02-0502]). Two more studies ([@b46-ol-08-02-0502],[@b50-ol-08-02-0502]) evaluating HPV infection in relation to neonatal prematurity and the mode of delivery remain unique in the field of pediatric HPV research. The first of these studies ([@b46-ol-08-02-0502]) did not find any significant evidence that maternal HPV infection is related to neonatal prematurity, while the other study ([@b50-ol-08-02-0502]) suggested that a caesarean section does not decrease the risk for oral HPV persistence in children. In a recent study, we used for the first time the term 'Trojan horse oncogenic strategy' to describe the physical history of HPV in childhood ([@b54-ol-08-02-0502]). This hypothesis that children act as a reservoir of silent high risk HPV types, analogous to the Trojan horse in Greek mythology, requires further investigation.

4. Future perspectives
======================

Following the approval of the two current vaccines against HPV ([@b55-ol-08-02-0502],[@b56-ol-08-02-0502]), a great expansion of studies involving HPV research and children was observed. These studies aimed to clarify several unresolved issues involving the efficacy and safety of the vaccination programmes against HPV ([@b57-ol-08-02-0502]--[@b60-ol-08-02-0502]). Moreover, they attempted to provide evidence to resolve the issues of whether or not the current target ages should be changed, and to determine the necessity of including boys into the vaccination programmes against HPV ([@b59-ol-08-02-0502],[@b60-ol-08-02-0502]). Epidemiological studies aim to determine the factors that influence the participation of adolescents into the vaccination programmes against HPV and propose scheduled strategies to increase this participation. As the vaccination period has already begun, a re-evaluation of the potential modes of HPV transmission in infancy and the physical history of HPV-associated infections in childhood is expected. In the future, further research is required to fully investigate and clarify all these issues, highlighting the fact that the paediatric story of HPV remains a challenging research target for the next generation of researchers. Indeed, the war against HPV continues.
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HPV pre-vaccination research and children: a brief overview.

  Year of publication   Authors/(Refs.)                                Contribution
  --------------------- ---------------------------------------------- -------------------------------------------------------------------
  1978                  Pfister and zur Hausen ([@b5-ol-08-02-0502])   HPV types in skin warts in children
  1981                  Costa *et al* ([@b17-ol-08-02-0502])           HPV types in juvenile RRP
  1982                  Braun *et al* ([@b18-ol-08-02-0502])           HPV types in juvenile RRP
                        Mounts *et al* ([@b19-ol-08-02-0502])          HPV types in juvenile RRP
  1986                  Roman and Fife ([@b20-ol-08-02-0502])          HPV types in foreskin in neonates
                        Rock *et al* ([@b21-ol-08-02-0502])            HPV types in genital warts in children
  1987                  Vallejos *et al* ([@b22-ol-08-02-0502])        HPV types in genital warts in children
  1988                  Steinberg ([@b23-ol-08-02-0502])               HPV types in genital warts in children
  1989                  Hanson *et al* ([@b24-ol-08-02-0502])          HPV mother-to-infant transmission
                        Sedlacek *et al* ([@b25-ol-08-02-0502])        HPV mother-to-infant transmission
  1990                  Gibson *et al* ([@b26-ol-08-02-0502])          HPV types in genital warts in children
                        Padel *et al* ([@b27-ol-08-02-0502])           HPV types in genital warts in children
                        Jenison *et al* ([@b28-ol-08-02-0502])         HPV types in oral samples in asymptomatic children
  1991                  Smith *et al* ([@b29-ol-08-02-0502])           HPV mother-to-infant transmission
  1993                  Fredericks *et al* ([@b30-ol-08-02-0502])      HPV mother-to-infant transmission
  1994                  Pakarian *et al* ([@b31-ol-08-02-0502])        HPV mother-to-infant transmission
                        Kaye *et al* ([@b32-ol-08-02-0502])            HPV viral load as a determinant for mother-to-infant transmission
  1995                  Cason *et al* ([@b33-ol-08-02-0502])           HPV mother-to-infant transmission
  1996                  Alberico *et al* ([@b34-ol-08-02-0502])        HPV mother-to-infant transmission
  1998                  Tseng *et al* ([@b35-ol-08-02-0502])           Evaluation of HPV infection and mode of delivery
  2000                  Rice *et al* ([@b36-ol-08-02-0502])            HPV types in oral samples in asymptomatic children
  2005                  Rintala *et al* ([@b37-ol-08-02-0502])         HPV mother-to-infant transmission
                        Chen *et al* ([@b38-ol-08-02-0502])            HPV types in tonsils in asymptomatic children
  2006                  Sisk *et al* ([@b39-ol-08-02-0502])            HPV types in tonsils in asymptomatic children
                        Mammas *et al* ([@b40-ol-08-02-0502])          HPV types in tonsils in asymptomatic children
  2008                  Sarkola *et al* ([@b41-ol-08-02-0502])         Evaluation of HPV types in breast milk
                        Mammas *et al* ([@b42-ol-08-02-0502])          HPV types in skin warts in children
  2009                  Cazzaniga *et al* ([@b43-ol-08-02-0502])       Evaluation of HPV types in breast milk
  2010                  Mammas *et al* ([@b44-ol-08-02-0502])          HPV mother-to-infant transmission
                        Mammas *et al* ([@b45-ol-08-02-0502])          Novel HPV types in juvenile RRP
                        Mammas *et al* ([@b46-ol-08-02-0502])          Evaluation of HPV infection and neonatal prematurity
  2011                  Mammas *et al* ([@b47-ol-08-02-0502])          HPV types in lower respiratory tract in children
                        Yoshida *et al* ([@b48-ol-08-02-0502])         Evaluation of HPV types in breast milk
                        Mammas *et al* ([@b49-ol-08-02-0502])          Evaluation of HPV types in breast milk
  2012                  Mammas *et al* ([@b50-ol-08-02-0502])          Evaluation of HPV persistence and mode of delivery

HPV, human papillomavirus; RRP, recurrent respiratory papillomatosis.
